Grantees of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have adapted a rapid and accurate new molecular typing strategy and used it to conduct one of the most comprehensive studies of adenoviruses ever performed in the United States.
At the Keystone Symposium in Cape Town, the Global HIV Vaccine Enterprise announced the appointment of its first executive director and the opening of a new secretariat in New York City. Dr. Alan Bernstein, founding president of the Canadian Institutes of Health Research, will lead the international alliance of researchers, funders and advocates dedicated to speeding the search for an HIV vaccine.
October 15, 2007, marks the fifth annual National Latino AIDS Awareness Day. On this day, the National Institute of Allergy and Infectious Diseases (NIAID) pledges to continue working toward reducing the burden of HIV/AIDS in the Latino community in the United States.
MIT Holding, Inc. (OTCBB: MITD), in collaboration with MEVLABS and Georgia Southern University, have successfully tested prototype designs of the patent pending PROVECTOR™. This small dispensable device is designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly diseases such as malaria, dengue fever, and West Nile virus.
A combination of drugs widely used to treat infections caused by HIV appears to stop brain damage caused by the virus as well, according to a study published in the Oct. 9, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
A team led by researchers at the UCSF Positive Health Program has been named to receive $15 million over five years to expand understanding of the complex interactions between HIV and the immune systems of newly infected patients following HIV transmission.
GlaxoSmithKline and Anacor Pharmaceuticals announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialisation of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor’s proprietary boron-based chemistry for use against selected targets.
Many Americans are familiar with the E. coli bacterium. Tales of tainted spinach and recalled hamburger sending hundreds of people to the hospital are becoming an all-too-common occurrence. In 2006, three people died and hundreds more were sickened across the country after eating E. coli-contaminated spinach.
India and the United States agreed to enhance cooperation in development of low-cost diagnostic and therapeutic medical technologies.
The National Institute of Allergy and Infectious Diseases at the National Institutes of Health has awarded the University of Georgia College of Veterinary Medicine a $1.18 million grant to develop rabies virus vaccines. This award is the continuation of a previous four-year $837,000 grant issued by NIAID in 2002 to initiate the study.